Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 1.00 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.73 |
| ▸ | VHL | P40337 | 1/20 | 0.73 |
| ▸ | CDK7 | P50613 | 1/20 | 0.73 |
| ▸ | CCNH | P51946 | 1/20 | 0.73 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26011120 | 1.00 | KRAS (1.00) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL25905190 | 1.00 | KRAS (1.00) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL26011095 | 1.00 | KRAS (1.00) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL30545254 | 1.00 | KRAS (1.00) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL19948226 | 1.00 | KRAS (1.00) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL31716398 | 1.00 | KRAS (1.00) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL19948108 | 1.00 | KRAS (1.00) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL19948124 | 1.00 | KRAS (1.00) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL29402492 | 1.00 | KRAS (1.00) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL26011086 | 1.00 | KRAS (1.00) | KRASSOS1VHLCDK7CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257374-A1 | NOVEL KRAS G12C PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | INNOVENT BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257374-A1 | NOVEL KRAS G12C PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | KRAS, NRAS, RASGRP1 | KRAS 1/4885SOS1 294/4885VHL 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.